Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael P Sanderson

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Cancer Chemotherapy and Pharmacology|May 11, 2016
A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniquesMelanie I Titze, Otmar Schaaf, Marco H Hofmann, et al.
European Journal of Immunology|August 11, 2011
Induced Syk deletion leads to suppressed allergic responses but has no effect on neutrophil or monocyte migration in vivoEva Wex, Thierry Bouyssou, Matthias J Duechs, et al.
The Biochemical Journal|October 19, 2005
A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44Alexander Stoeck, Sascha Keller, Svenja Riedle, et al.
The Journal of Biological Chemistry|October 28, 2004
ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influxMichael P Sanderson, Sarah N Erickson, Peter J Gough, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 23, 2022
Translational PK/PD Modeling of Tumor Growth Inhibition and Target Inhibition to Support Dose Range Selection of the LMP7 Inhibitor M3258 in Relapsed/Refractory Multiple MyelomaFloriane Lignet, Christina Esdar, Gina Walter-Bausch, et al.
Journal of Medicinal Chemistry|July 6, 2021
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i)Markus Klein, Michael Busch, Manja Friese-Hamim, et al.
Molecular Cancer Therapeutics|May 28, 2021
M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma ModelsMichael P Sanderson, Manja Friese-Hamim, Gina Walter-Bausch, et al.
European Journal of Cancer (Oxford, England : 1990)|May 13, 2021
FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor responseOlga Bogatyrova, Johanna S M Mattsson, Edith M Ross, et al.
Iscience|December 11, 2020
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET AlterationsLinda Pudelko, Frank Jaehrling, Christof Reusch, et al.
Molecular Cancer Therapeutics|October 7, 2015
BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose HomeostasisMichael P Sanderson, Joshua Apgar, Pilar Garin-Chesa, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Cancer Chemotherapy and Pharmacology|May 11, 2016
A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniquesMelanie I Titze, Otmar Schaaf, Marco H Hofmann, et al.
European Journal of Immunology|August 11, 2011
Induced Syk deletion leads to suppressed allergic responses but has no effect on neutrophil or monocyte migration in vivoEva Wex, Thierry Bouyssou, Matthias J Duechs, et al.
The Biochemical Journal|October 19, 2005
A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44Alexander Stoeck, Sascha Keller, Svenja Riedle, et al.
The Journal of Biological Chemistry|October 28, 2004
ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influxMichael P Sanderson, Sarah N Erickson, Peter J Gough, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 23, 2022
Translational PK/PD Modeling of Tumor Growth Inhibition and Target Inhibition to Support Dose Range Selection of the LMP7 Inhibitor M3258 in Relapsed/Refractory Multiple MyelomaFloriane Lignet, Christina Esdar, Gina Walter-Bausch, et al.
Journal of Medicinal Chemistry|July 6, 2021
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i)Markus Klein, Michael Busch, Manja Friese-Hamim, et al.
Molecular Cancer Therapeutics|May 28, 2021
M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma ModelsMichael P Sanderson, Manja Friese-Hamim, Gina Walter-Bausch, et al.
European Journal of Cancer (Oxford, England : 1990)|May 13, 2021
FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor responseOlga Bogatyrova, Johanna S M Mattsson, Edith M Ross, et al.
Iscience|December 11, 2020
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET AlterationsLinda Pudelko, Frank Jaehrling, Christof Reusch, et al.
Molecular Cancer Therapeutics|October 7, 2015
BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose HomeostasisMichael P Sanderson, Joshua Apgar, Pilar Garin-Chesa, et al.
Pageof 3